{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:18Z","timestamp":1791232458987,"version":"4.1.0"},"reference-count":91,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi (Spain)","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Diabetes mellitus (DM) is one of the most common comorbid conditions in persons with COVID-19 and a risk factor for poor prognosis. The reasons why COVID-19 is more severe in persons with DM are currently unknown although the scarce data available on patients with DM hospitalized because of COVID-19 show that glycemic control is inadequate. The fact that patients with COVID-19 are usually cared for by health professionals with limited experience in the management of diabetes and the need to prevent exposure to the virus may also be obstacles to glycemic control in patients with COVID-19. Effective clinical care should consider various aspects, including screening for the disease in at-risk persons, education, and monitoring of control and complications. We examine the effect of COVID-19 on DM in terms of glycemic control and the restrictions arising from the pandemic and assess management of diabetes and drug therapy in various scenarios, taking into account factors such as physical exercise, diet, blood glucose monitoring, and pharmacological treatment. Specific attention is given to patients who have been admitted to hospital and critically ill patients. Finally, we consider the role of telemedicine in the management of DM patients with COVID-19 during the pandemic and in the future.<\/jats:p>","DOI":"10.3390\/jcm10225341","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T11:32:03Z","timestamp":1637062323000},"page":"5341","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["COVID-19 and Diabetes"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-043X","authenticated-orcid":false,"given":"Virginia","family":"Bellido","sequence":"first","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital Universitario Virgen del Roc\u00edo, 41013 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-1143","authenticated-orcid":false,"given":"Antonio","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Endocrinology and Nutrition Department, Hospital de la Santa Creu i Sant Pau, Institut d\u2019Investigaci\u00f3 Bio-M\u00e8dica Sant Pau, 08041 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Universitat Aut\u00f2noma de Barcelona, 08193 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40618-020-01236-2","article-title":"Prevalence and impact of diabetes among people infected with SARS- CoV-2","volume":"43","author":"Fadini","year":"2020","journal-title":"J. Endocrinol. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"104354","DOI":"10.1016\/j.jcv.2020.104354","article-title":"Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome","volume":"127","author":"Roncon","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dsx.2020.04.004","article-title":"Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00392-020-01626-9","article-title":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China","volume":"109","author":"Li","year":"2020","journal-title":"Clin. Res. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-8587(20)30272-2","article-title":"Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study","volume":"8","author":"Barron","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Moazzami, B., Chaichian, S., Kasaeian, A., Djalalinia, S., Akhlaghdoust, M., Eslami, M., and Broumand, B. (2020). Metabolic risk factors and risk of COVID-19: A systematic review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0243600"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.dsx.2020.04.018","article-title":"Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia. A systematic review, meta-analysis, and meta-regression","volume":"14","author":"Huang","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/1753-0407.13027","article-title":"Diabetes and COVID-19","volume":"12","author":"Bloomgarden","year":"2020","journal-title":"J. Diabetes"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1377\/hlthaff.2020.00426","article-title":"The potential health care costs and resource use associated with COVID-19 in The United States","volume":"39","author":"Bartsch","year":"2020","journal-title":"Health Aff."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E736","DOI":"10.1152\/ajpendo.00124.2020","article-title":"Covid-19 pandemic, coronaviruses, and diabetes mellitus","volume":"318","author":"Muniyappa","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2337\/dc20-1857","article-title":"Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: A multicenter, retrospective hospital-based analysis","volume":"44","author":"Klonoff","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/07853890.2020.1836566","article-title":"Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: Data from the Spanish SEMI-COVID-19 Registry","volume":"53","author":"Buonaiuto","year":"2021","journal-title":"Ann. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc20-0723","article-title":"Outcomes in patients with hyperglycemia affected by COVID-19: Can we do more on glycemic control?","volume":"43","author":"Sardu","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108125","DOI":"10.1016\/j.diabres.2020.108125","article-title":"COVID-19 and diabetes: Can DPP4 inhibition play a role?","volume":"162","author":"Iacobellis","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2337\/dc20-0643","article-title":"Exploring diseases\/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: A Mendelian randomization analysis highlights tentative relevance of diabetes-related traits","volume":"43","author":"Rao","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.mce.2008.09.020","article-title":"The sweeter side of ACE2: Physiological evidence for a role in diabetics","volume":"301","author":"Bindom","year":"2009","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/1932296820924469","article-title":"Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States","volume":"14","author":"Bode","year":"2020","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"154216","DOI":"10.1016\/j.metabol.2020.154216","article-title":"Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China","volume":"107","author":"Zhou","year":"2020","journal-title":"Metabolism"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cen.14288","article-title":"COVID-19 and diabetes: Insulin requirements parallel illness severity in critically unwell patients","volume":"93","author":"Wu","year":"2020","journal-title":"Clin. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.dsx.2020.08.015","article-title":"Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature","volume":"14","author":"Pal","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00592-009-0109-4","article-title":"Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes","volume":"47","author":"Yang","year":"2010","journal-title":"Acta Diabetol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/dom.14057","article-title":"COVID-19 infection may cause ketosis and ketoacidosis","volume":"22","author":"Li","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","article-title":"COVID-19 and diabetes mellitus: From pathophysiology to clinical management","volume":"17","author":"Lim","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1753-0407.12090","article-title":"Glucocorticoid-induced hyperglycemia","volume":"6","author":"Perez","year":"2014","journal-title":"J. Diabetes"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.diabet.2020.05.008","article-title":"Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports","volume":"46","author":"Scheen","year":"2020","journal-title":"Diabetes Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"108348","DOI":"10.1016\/j.diabres.2020.108348","article-title":"Impact of COVID-19 lockdown on glycemic control in patients with type 1 diabetes","volume":"166","author":"Bellido","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.2337\/dc20-1127","article-title":"Blood glucose control during lockdown for COVID-19: CGM metrics in Italian adults with type 1 diabetes","volume":"43","author":"Capaldo","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"109066","DOI":"10.1016\/j.diabres.2021.109066","article-title":"Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: A meta-analysis of observational studies","volume":"180","author":"Garofolo","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"107748","DOI":"10.1016\/j.jdiacomp.2020.107748","article-title":"The early impact of the COVID-19 pandemic on adults with type 1 or type 2 diabetes: A national cohort study","volume":"34","author":"Fisher","year":"2020","journal-title":"J. Diabetes Complicat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108547","DOI":"10.1016\/j.diabres.2020.108547","article-title":"People living with type 1 diabetes point of view in COVID-19 times (covidT1 study): Disease impact, health system pitfalls and lessons for the future","volume":"171","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00592-020-01637-y","article-title":"Short-term impact of COVID-19 lockdown on metabolic control of patients with well-controlled type 2 diabetes: A single-centre observational study","volume":"58","author":"Biancalana","year":"2021","journal-title":"Acta Diabetol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2213-8587(21)00116-9","article-title":"Impact of COVID-19 on diagnoses, monitoring and mortality in people with type 2 diabetes: A UK-wide cohort study involving 14 million people in primary care","volume":"9","author":"Carr","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/dom.14293","article-title":"Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany","volume":"23","author":"Jacob","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"108118","DOI":"10.1016\/j.diabres.2020.108118","article-title":"Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed","volume":"162","author":"Wang","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1007\/s00125-020-05164-x","article-title":"Prevention and management of COVID-19 among patients with diabetes: An appraisal of the literature","volume":"63","author":"Katulanda","year":"2020","journal-title":"Diabetologia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.dsx.2021.02.026","article-title":"COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges","volume":"15","author":"Pal","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_39","unstructured":"Marfella, R., D\u2019Onofrio, N., Sardu, C., Scisciola, L., Maggi, P., Coppola, N., Romano, C., Messina, V., Turriziani, F., and Siniscalchi, M. (2021). Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study. Diabetes Obes. Metab."},{"key":"ref_40","first-page":"73","article-title":"Executive summary: Updates to the dietary treatment of prediabetes and type 2 diabetes mellitus","volume":"33","year":"2021","journal-title":"Clin. Investig. Arteriosler."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.endinu.2018.10.010","article-title":"Documento de abordaje integral de la diabetes tipo 2","volume":"66","year":"2019","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"584642","DOI":"10.3389\/fendo.2020.584642","article-title":"The urgent need for recommending physical activity for the management of diabetes during and beyond COVID-19 outbreak","volume":"11","author":"Fernandes","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_43","unstructured":"Kokkinos, P., and Narayan, P. (2010). Exercise metabolism in health and disease. Cardiorespiratory Fitness in Cardiometabolic Diseases, Springer."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Koliaki, C., Tentolouris, A., Eleftheriadou, I., Melidonis, A., Dimitriadis, G., and Tentolouris, N. (2020). Clinical management of diabetes mellitus in the era of COVID-19: Practical issues, peculiarities and concerns. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072288"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"108142","DOI":"10.1016\/j.diabres.2020.108142","article-title":"COVID-19 and diabetes: Knowledge in progress","volume":"162","author":"Hussain","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2021). 6. Glycemic targets-Standards of medical care in diabetes\u20142021. Diabetes Care, 44, S73\u2013S84.","DOI":"10.2337\/dc21-S006"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical recommendations for the management of diabetes in patients with COVID-19","volume":"8","author":"Bornstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.2337\/dc15-1096","article-title":"Effect of acetaminophen on CGM glucose in an outpatient setting","volume":"38","author":"Maahs","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"592439","DOI":"10.3389\/fphar.2020.592439","article-title":"Perspectives of antidiabetic drugs in diabetes with coronavirus infections","volume":"11","author":"Sun","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s00125-020-05180-x","article-title":"Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: The CORONADO study","volume":"63","author":"Cariou","year":"2020","journal-title":"Diabetologia"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Belmonte, L.M., Torres-Pe\u00f1a, J.D., L\u00f3pez-Carmona, M.D., Ayala-Guti\u00e9rrez, M.M., Fuentes-Jim\u00e9nez, F., Huerta, L.J., Mu\u00f1oz, J.A., Rubio-Rivas, M., Madrazo, M., and Guzm\u00e1n Garc\u00eda, M. (2020). Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: A nationwide cohort study. BMC Med., 18.","DOI":"10.1186\/s12916-020-01832-2"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: Current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.aace.2020.11.019","article-title":"Euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT2 inhibitors","volume":"7","author":"Vitale","year":"2021","journal-title":"AACE Clin. Case Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2337\/dc12-2060","article-title":"Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? The time has come for GLP-1 receptor agonists!","volume":"36","author":"Schwartz","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12933-020-01090-9","article-title":"Treating type 2 diabetes in COVID-19 patients: The potential benefits of injective therapies","volume":"19","author":"Longo","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_59","first-page":"1769","article-title":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence?","volume":"323","author":"Patel","year":"2020","journal-title":"JAMA"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S2468-1253(20)30084-4","article-title":"COVID-19 and the liver: Little cause for concern","volume":"5","author":"Bangash","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2337\/dc20-0941","article-title":"Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era","volume":"43","author":"Ceriello","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1007\/s12325-020-01417-8","article-title":"Challenging issues in the management of cardiovascular risk factors in diabetes during the COVID-19 pandemic: A review of current literature","volume":"37","author":"Rahimi","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.2337\/dc20-1088","article-title":"Type 1 diabetes and COVID-19: Preliminary findings from a multicenter surveillance study in the U.S","volume":"43","author":"Ebekozien","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/clinem\/dgaa342","article-title":"A pragmatic approach to inpatient diabetes management during the COVID-19 pandemic","volume":"105","author":"Korytkowski","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13300-020-00966-z","article-title":"Inpatient hyperglycemia management and COVID-19","volume":"12","author":"Bellido","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2020). 15 Diabetes care in the hospital-Standards of medical care in diabetes\u20142020. Diabetes Care, 43, S193\u2013S202.","DOI":"10.2337\/dc20-S015"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2337\/dc15-0303","article-title":"Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG Trial","volume":"38","author":"Cardona","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4158\/EP161532.OR","article-title":"Safety and efficacy of personalized glycemic control in critically ill patients: A 2-year before and after intervention trial","volume":"23","author":"Krinsley","year":"2017","journal-title":"Endocr. Pract."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/MJT.0000000000001078","article-title":"Insulin therapy in hospitalized patients","volume":"27","author":"Ramos","year":"2020","journal-title":"Am. J. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1932296820923045","article-title":"Individualizing inpatient diabetes management during the coronavirus disease 2019 pandemic","volume":"14","author":"Pasquel","year":"2020","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.2337\/dc20-0944","article-title":"Early observation and mitigation of challenges in diabetes management of COVID-19 patients in critical care units","volume":"43","author":"Hamdy","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/dc09-9029","article-title":"American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control","volume":"32","author":"Moghissi","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_73","first-page":"465","article-title":"Hospital management of hyperglycemia","volume":"132","year":"2009","journal-title":"Med. Clin."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2337\/dc10-2023","article-title":"Transition from intravenous to subcutaneous insulin: Effectiveness and safety of a standardized protocol and predictors of outcome in patients with acute coronary syndrome","volume":"34","author":"Avanzini","year":"2011","journal-title":"Diabetes Care."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.endinu.2017.08.005","article-title":"Transition from intravenous insulin to subcutaneous long-acting insulin in critical care patients on enteral or parenteral nutrition","volume":"64","author":"Ramos","year":"2017","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 (DARE-19): A randomized, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: Consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref_78","unstructured":"FDA (2021, March 02). FAQs on Home-Use Blood Glucose Meters Utilized within Hospitals during the COVID-19 Pandemic, Available online: https:\/\/www.fda.gov\/medical-devices\/coronavirus-covid-19-and-medical-devices\/using-home-use-blood-glucose-meters-hospitals-during-covid-19-pandemic."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/1932296820930210","article-title":"Glucose monitoring and diabetes management in the time of coronavirus disease 2019","volume":"14","author":"Welsh","year":"2020","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_80","unstructured":"Dexcom (2021, March 02). Fact Sheet for Healthcare Providers: Use of Dexcom Continuous Glucose Monitoring Systems during the COVID-19 Pandemic. Available online: https:\/\/www.dexcom.com\/hospitalfacts."},{"key":"ref_81","unstructured":"Abbott (2020, March 25). Press release. FreeStyle Libre: Diabetes Care during COVID-19. Available online: https:\/\/www.abbott.com\/corpnewsroom\/product-and-innovation\/freestyle-libre-diabetes-care-during-covid-19.html."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.2337\/dc19-2073","article-title":"Comparison of the FreeStyle Libre pro flash continuous glucose monitoring (CGM) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen","volume":"43","author":"Galindo","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.2337\/dc20-1016","article-title":"Glucose as the fifth vital sign: A randomized controlled trial of continuous glucose monitoring in a non-ICU hospital setting","volume":"43","author":"Fortmann","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.2337\/dc20-0840","article-title":"Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: The glucose telemetry system, a randomized clinical trial","volume":"43","author":"Singh","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.2337\/dc20-1503","article-title":"Feasibility of inpatient continuous glucose monitoring during the COVID-19 pandemic: Early experience","volume":"43","author":"Reutrakul","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2337\/dc20-2219","article-title":"Continuous glucose monitoring in the intensive care unit during the COVID-19 pandemic","volume":"44","author":"Agarwal","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1932296820932903","article-title":"Implementation of continuous glucose monitoring in the hospital: Emergent considerations for remote glucose monitoring during the COVID-19 pandemic","volume":"14","author":"Galindo","year":"2020","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1177\/1932296820954163","article-title":"Continuous glucose monitors and automated insulin dosing systems in the Hospital Consensus Guideline","volume":"14","author":"Galindo","year":"2020","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e2021476","DOI":"10.1001\/jamanetworkopen.2020.21476","article-title":"Use and content of primary care office-based vs telemedicine care visits during the COVID-19 pandemic in the US","volume":"3","author":"Alexander","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"E341","DOI":"10.1503\/cmaj.150885","article-title":"Effect of telemedicine on glycated hemoglobin in diabetes: A systematic review and meta-analysis of randomized trials","volume":"189","author":"Faruque","year":"2017","journal-title":"CMAJ."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/tmj.2018.0128","article-title":"Clinical effectiveness of telemedicine in diabetes mellitus: A meta-analysis of 42 randomized controlled trials","volume":"25","author":"Tchero","year":"2019","journal-title":"Telemed. J. E Health"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/22\/5341\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:31:18Z","timestamp":1760167878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/22\/5341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":91,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["jcm10225341"],"URL":"https:\/\/doi.org\/10.3390\/jcm10225341","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]}}}